NASDAQ: PMVP
Pmv Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for PMVP

Based on 1 analyst offering 12 month price targets for Pmv Pharmaceuticals Inc

Min Forecast
$5.00+247.22%
Avg Forecast
$5.00+247.22%
Max Forecast
$5.00+247.22%

Should I buy or sell PMVP stock?

Based on 1 analyst offering ratings for Pmv Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PMVP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PMVP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PMVP stock forecasts and price targets.

PMVP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-20

1 of 1

Forecast return on equity

Is PMVP forecast to generate an efficient return?

Company
-2.88%
Industry
232.67%
Market
89.3%
PMVP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PMVP forecast to generate an efficient return on assets?

Company
-2.55%
Industry
34.37%
PMVP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PMVP earnings per share forecast

What is PMVP's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.57
Avg 3 year Forecast
-$0.98

PMVP revenue forecast

What is PMVP's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$33.1M
Avg 2 year Forecast
$70.8M
Avg 3 year Forecast
$113.5M

PMVP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PMVP$1.44$5.00+247.22%Buy
CBUS$2.52$22.17+779.64%Strong Buy
AVTE$2.60N/AN/A
ARMP$2.04$7.00+243.14%Buy
QNCX$1.67$9.50+468.86%Strong Buy

Pmv Pharmaceuticals Stock Forecast FAQ

Is Pmv Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PMVP) stock is to Buy PMVP stock.

Out of 1 analyst, 0 (0%) are recommending PMVP as a Strong Buy, 1 (100%) are recommending PMVP as a Buy, 0 (0%) are recommending PMVP as a Hold, 0 (0%) are recommending PMVP as a Sell, and 0 (0%) are recommending PMVP as a Strong Sell.

If you're new to stock investing, here's how to buy Pmv Pharmaceuticals stock.

What is PMVP's earnings growth forecast for 2025-2027?

(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.95%.

Pmv Pharmaceuticals's earnings in 2025 is -$51,465,000.On average, 5 Wall Street analysts forecast PMVP's earnings for 2025 to be -$80,104,557, with the lowest PMVP earnings forecast at -$92,109,891, and the highest PMVP earnings forecast at -$57,439,314. On average, 2 Wall Street analysts forecast PMVP's earnings for 2026 to be -$81,242,994, with the lowest PMVP earnings forecast at -$100,389,432, and the highest PMVP earnings forecast at -$62,096,556.

In 2027, PMVP is forecast to generate -$50,712,187 in earnings, with the lowest earnings forecast at -$50,712,187 and the highest earnings forecast at -$50,712,187.

What is PMVP's revenue growth forecast for 2027-2029?

(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.7%.

Pmv Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PMVP's revenue for 2027 to be $1,712,830,003, with the lowest PMVP revenue forecast at $1,712,830,003, and the highest PMVP revenue forecast at $1,712,830,003. On average, 1 Wall Street analysts forecast PMVP's revenue for 2028 to be $3,663,696,804, with the lowest PMVP revenue forecast at $3,663,696,804, and the highest PMVP revenue forecast at $3,663,696,804.

In 2029, PMVP is forecast to generate $5,873,299,255 in revenue, with the lowest revenue forecast at $5,873,299,255 and the highest revenue forecast at $5,873,299,255.

What is PMVP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PMVP) forecast ROA is -2.55%, which is lower than the forecast US Biotechnology industry average of 34.37%.

What is PMVP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PMVP price target, the average PMVP price target is $5.00, with the highest PMVP stock price forecast at $5.00 and the lowest PMVP stock price forecast at $5.00.

The Wall Street analyst predicted that Pmv Pharmaceuticals's share price could reach $5.00 by Aug 20, 2025. The average Pmv Pharmaceuticals stock price prediction forecasts a potential upside of 247.22% from the current PMVP share price of $1.44.

What is PMVP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PMVP) Pmv Pharmaceuticals's current Earnings Per Share (EPS) is -$1.00. On average, analysts forecast that PMVP's EPS will be -$1.55 for 2025, with the lowest EPS forecast at -$1.78, and the highest EPS forecast at -$1.11. On average, analysts forecast that PMVP's EPS will be -$1.57 for 2026, with the lowest EPS forecast at -$1.94, and the highest EPS forecast at -$1.20. In 2027, PMVP's EPS is forecast to hit -$0.98 (min: -$0.98, max: -$0.98).

What is PMVP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PMVP) forecast ROE is -2.88%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.